Zip Co (ASX:ZIP), BrainChip (ASX:BRN) and Gentrack (ASX:GTK): What Do the Latest Updates Show for Three Technology Names?

Sonal Goyal

26 October 2026 09:12 PM AEDT

Zip Co (ASX:ZIP), BrainChip (ASX:BRN) and Gentrack (ASX:GTK): What Do the Latest Updates Show for Three Technology Names?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Zip Co (ASX:ZIP) traded at $1.62, up 10.96%, on volume of 59,171,083 shares during the 26 October 2026 session.
BrainChip (ASX:BRN) made its Sequora edge AI processor IP commercially available, while Gentrack (ASX:GTK) signed Momentum Energy for its g2 billing platform.
Zip's 1Q27 total transaction volume was $4.6 billion, up 18.0%, with FY27 cash EBTDA guidance of $340 million reconfirmed.

Zip Co Limited (ASX:ZIP) traded at $1.62, up 10.96%, on volume of 59,171,083 shares during the trading session on 26 October 2026. BrainChip Holdings Ltd (ASX:BRN) traded at $0.11, down 4.35%, on volume of 5,006,977 shares, and Gentrack Group Limited (ASX:GTK) traded at $3.58, up 1.99%, on volume of 608,120 shares. Each stock recorded unusual volume, meaning trading volume at least 50% above its average daily volume over the last month. Zip is a buy-now-pay-later provider, BrainChip develops neuromorphic edge AI processors, and Gentrack supplies billing software to utilities.

Zip Co: First Quarter FY27 Update Dated 23 October 2026

Zip reported total transaction volume of $4.6 billion for the quarter ended 30 September 2026, up 18.0%, with US volume up 34.1% in US dollars. Total income was $376.1 million, up 17.0%, revenue margin was 8.2%, and transactions rose 21.8% to 31.6 million. Net bad debts were 1.97% of transaction volume, against 1.65% a year earlier, and cash net transaction margin was 3.8% compared with 4.0%.

Cash EBTDA was $65.0 million, up 3.4%, and includes $10.1 million of operating expenses linked to an external fraud event in the US. Excluding those costs, adjusted cash EBTDA was $75.1 million, up 19.5%. Operating margin was 17.3% against 19.5%. Active customers were 6.4 million and merchants 96,600. The company reconfirmed FY27 guidance of group cash EBTDA of $340 million, a target range of 1.5% to 2.0% for US credit losses, and progress on a $50 million on-market buy-back. It also noted its first US asset-backed securities issuance and the wind-down of its New Zealand business, which began in July 2026.

BrainChip: Sequora Processor IP Released on 14 October 2026

BrainChip announced that its Sequora processor intellectual property core has completed development and is available for commercial licensing to semiconductor and system developers. The company says Sequora brings generative AI and large language model capabilities to edge devices, supports models up to about 3 billion parameters, and retains the ultra-low power and cloud-independent features of its Akida technology.

The product is offered as IP that customers incorporate into their own system-on-chip designs, with software and development tools. BrainChip stated that it has begun customer engagement but is not in a position to provide reliable forecasts of future licensing revenue, customer adoption or financial impact, and that any material contracts will be disclosed under its continuous disclosure obligations.

Gentrack: Momentum Energy Contract Announced on 20 October 2026

Gentrack announced that Momentum Energy has contracted with it to support more than 200,000 residential and business meter points across Australia on its g2 billing solution, following a competitive evaluation. The release cites Gentrack's delivery record in the Australian energy market, its regulatory compliance model and its integration with Salesforce. Momentum will use g2 to simplify its technology landscape and reduce the cost to serve. The announcement does not state contract value or timing.

About the Companies

Zip Co operates in Australia and the United States, with the US the larger contributor to transaction volume. BrainChip, listed on the ASX and quoted on the OTCQX, describes itself as a leader in ultra-low power, event-based neuromorphic AI and sells its Akida processor technology as licensed IP. Gentrack is listed on both the NZX and the ASX and supplies customer and billing platforms to utilities in Australia and New Zealand.

Risks

Zip's net bad debts and operating margin moved the wrong way against the prior year, and the quarter included an external fraud event that the company says temporarily moderated US growth in July and August. BrainChip has said it cannot yet forecast licensing revenue from Sequora. Gentrack's release gives no contract value, so the financial effect of the Momentum agreement is not disclosed.

Catalysts on Investors' Radar

Zip's launch of Zip Cash to select customers over the holiday season and its second-quarter credit loss target are the items it has named. BrainChip will report customer developments as they occur, and Gentrack's onboarding of Momentum will follow implementation timelines not yet set out in the release.

Final Perspective

The three technology companies traded on unusually high volume on the same day, with Zip recording the largest share price gain of the group. Each has a recent update on record, covering quarterly results, a product release and a new customer contract.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.